Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 29, 2021 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Appoints Pharmaceutical Executive Molly Harper to its Board of Directors

CORAL GABLES, Fla., June 29, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
June 28, 2021 16:30 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Comments on Recent Decision by Health Canada to Re-issue an NOC for Ruzurgi®

CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
June 28, 2021 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Exclusive License and Supply Agreement with DyDo Pharma for the Development and Commercialization of Firdapse® in Japan

CORAL GABLES, Fla., June 28, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on...
June 03, 2021 13:20 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals, Inc.’s and KYE Pharmaceuticals’ Lawsuit in Canadian Federal Court Quashes the Notice of Compliance (NOC) for Ruzurgi®

- Without an NOC, Ruzurgi® is without a Marketing Authorization in Canada - Matter Remanded Back to Health Canada to Provide a More Transparent Record of Its Decision in Light of Firdapse®’s Data...
May 19, 2021 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

CORAL GABLES, Fla., May 19, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
May 10, 2021 17:29 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces First Quarter 2021 Financial Results and Provides Business Update

-Firdapse® Q1 2021 Net Revenues of $30.2 Million -First Quarter 2021 GAAP Net Income of $7.7 Million; Non-GAAP Net Income of $11.6 Million -Recently Received Orphan Drug Designation for Firdapse® in...
May 03, 2021 08:05 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold First Quarter 2021 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, May 11th, 2021

CORAL GABLES, Fla., May 03, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing,...
March 22, 2021 08:03 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces $40 Million Share Repurchase Program

CORAL GABLES, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq:CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing...
March 15, 2021 17:26 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals Announces Fourth Quarter and Year-End 2020 Financial Results and Provides Corporate Update

- Firdapse® Q4-20 Net Revenues of $31.0 Million, FY-20 Net Revenues of $119.1 Million - GAAP Net Income of $75.0 Million for Fiscal Year 2020 - $140.3 Million in Cash and Investments and No Funded...
March 04, 2021 11:00 ET | Source: Catalyst Pharmaceuticals, Inc.

Catalyst Pharmaceuticals to Hold Fourth Quarter and Year-End 2020 Financial Results and Corporate Update Conference Call and Webcast on Tuesday, March 16th, 2021

CORAL GABLES, Fla., March 04, 2021 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and...